BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18271927)

  • 21. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
    Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer.
    Husgafvel-Pursiainen K; Boffetta P; Kannio A; Nyberg F; Pershagen G; Mukeria A; Constantinescu V; Fortes C; Benhamou S
    Cancer Res; 2000 Jun; 60(11):2906-11. PubMed ID: 10850436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.
    Woenckhaus M; Klein-Hitpass L; Grepmeier U; Merk J; Pfeifer M; Wild P; Bettstetter M; Wuensch P; Blaszyk H; Hartmann A; Hofstaedter F; Dietmaier W
    J Pathol; 2006 Oct; 210(2):192-204. PubMed ID: 16915569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.
    Hainaut P; Pfeifer GP
    Carcinogenesis; 2001 Mar; 22(3):367-74. PubMed ID: 11238174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
    Husgafvel-Pursiainen K; Karjalainen A; Kannio A; Anttila S; Partanen T; Ojajärvi A; Vainio H
    Am J Respir Cell Mol Biol; 1999 Apr; 20(4):667-74. PubMed ID: 10100998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of p53 mutational spectra of esophageal squamous cell carcinomas from Linzhou, comparison with esophageal and other cancers from other areas].
    Wang LD; Liu B; Zheng S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Mar; 24(3):202-5. PubMed ID: 12816712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
    Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
    Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 gene mutations in non-small cell lung cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis.
    Zhao Y; Wu D; Xiang X; Zhang B; Zhou N; Hu Y
    Chin Med Sci J; 1999 Sep; 14(3):134-7. PubMed ID: 12903811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.
    Pfeifer GP; Denissenko MF; Olivier M; Tretyakova N; Hecht SS; Hainaut P
    Oncogene; 2002 Oct; 21(48):7435-51. PubMed ID: 12379884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
    Fujita T; Kiyama M; Tomizawa Y; Kohno T; Yokota J
    Int J Oncol; 1999 Nov; 15(5):927-34. PubMed ID: 10536175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.
    Hussain SP; Amstad P; Raja K; Sawyer M; Hofseth L; Shields PG; Hewer A; Phillips DH; Ryberg D; Haugen A; Harris CC
    Cancer Res; 2001 Sep; 61(17):6350-5. PubMed ID: 11522624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 and K-ras mutations in lung cancers from former and never-smoking women.
    Vähäkangas KH; Bennett WP; Castrén K; Welsh JA; Khan MA; Blömeke B; Alavanja MC; Harris CC
    Cancer Res; 2001 Jun; 61(11):4350-6. PubMed ID: 11389059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.